ľ¹Ï¸£ÀûÓ°ÊÓ

Cardiovascular disease (CVD) in women remains understudied, under-recognized, underdiagnosed, and undertreated. Despite being the leading cause of death in women worldwide, and although more women die of CVD than men, studies have shown that women are less likely to benefit from the same care as men. What’s the extent of these differences? What factors explain it? Do the sex differences in cardiovascular care reflect different optimal treatment options or do they reflect suboptimal care in women? 
 

This work explored the sex differences in guideline-recommended treatment for CVD prevention and management. The findings highlight sex differences in cardiovascular care, often to the disadvantage of women. Globally, women with acute coronary syndrome received less care than men. In clinical practice in the Netherlands, women had lower treatment and control of LDL cholesterol, were prescribed lower intensities of statins, were less likely to reach LDL-c targets or undergo treatment uptitration and more likely to discontinue statin therapy. Sex differences were also observed in the pharmacological management of hypertensive patients and suggest a need for identifying optimal dosing practice for each sex.